Alan Miller
Cardiovascular Disease · Jacksonville, FLNPI 1518934827
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $514,027 of the $547,240 with a category attached, or 93.9%. 22 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 48.9% of the total. Reporting peaked in 2020 at $227,390 and has fallen 99.4% since, to $1,412 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 241 payments — averaging $2270.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$268K
- Cvrx, Inc.$65K
- AstraZeneca$60K
- Abbott$50K
- AbbVie$49K
- Astrazeneca UK Limited$45K
- plus $10K from 16 others
Across 60 payments — averaging $3883.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$177K
- Merck$20K
- AbbVie$13K
- Mesoblast, Inc.$10K
- Cvrx, Inc.$7K
- Pfizer$6K
What the payments were for
- Consulting fees$514,02794%
- Speaking & faculty fees$3300%
- Travel & lodging$27,3255%
- Food & beverage$5,5591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 88 | $267,713 |
| Cvrx, Inc. | 15 | $65,227 |
| AstraZeneca | 6 | $59,876 |
| Abbott | 78 | $50,436 |
| AbbVie | 32 | $48,939 |
| Astrazeneca UK Limited | 2 | $44,840 |
| Impulse Dynamics (USA) Inc. | 1 | $7,352 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $1,400 |
| Pfizer | 1 | $330 |
| Stryker | 1 | $173 |
| Abiomed | 2 | $167 |
| Bridgebio Pharma, Inc. | 1 | $125 |
| Shockwave Medical, Inc | 1 | $124 |
| Heartflow, Inc. | 1 | $114 |
| Merck | 1 | $102 |
| Lundbeck LLC | 4 | $95 |
| Lexicon Pharmaceuticals, Inc. | 1 | $92 |
| Inspire Medical Systems, Inc. | 1 | $48 |
| Radius Health, Inc. | 1 | $30 |
| Dendreon Pharmaceuticals LLC | 1 | $24 |
| IBSA Pharma Inc. | 1 | $18 |
| Masimo Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$265,984
- Barostim Neo System$65,184
- CardioMEMS HF System$47,714
- Rinvoq$33,495
- OPTIMIZER$14,704
- EVUSHELD$4,296
- OFEV$1,400
- TRADJENTA$475
- VYNDAQEL$330
- CARDIOMEMS$225
- VERQUVO$204
- FlowTriever$173
- Impella$132
- Attruby$125
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$124
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$118
- FFRct$114
How this compares
$547,240 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 11 | $7,769 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $364 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $270 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Jacksonville
- Samer GarasJacksonville$258K
- Jose Nativi-NicolauJacksonville$125K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.